The Sodium-Glucose Cotransporter-2 Inhibitor Canagliflozin Alleviates Endothelial Dysfunction Following <i>In Vitro</i> Vascular Ischemia/Reperfusion Injury in Rats
Vascular ischemia/reperfusion injury (IRI) contributes to graft failure and adverse clinical outcomes following coronary artery bypass grafting. Sodium-glucose-cotransporter (SGLT)-2-inhibitors have been shown to protect against myocardial IRI, irrespective of diabetes. We hypothesized that adding c...
Main Authors: | Sevil Korkmaz-Icöz, Cenk Kocer, Alex A. Sayour, Patricia Kraft, Mona I. Benker, Sophia Abulizi, Adrian-Iustin Georgevici, Paige Brlecic, Tamás Radovits, Sivakkanan Loganathan, Matthias Karck, Gábor Szabó |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-07-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/22/15/7774 |
Similar Items
-
Acute canagliflozin treatment protects against in vivo myocardial ischemia–reperfusion injury in non-diabetic male rats and enhances endothelium-dependent vasorelaxation
by: Alex Ali Sayour, et al.
Published: (2019-04-01) -
EMPA-REG OUTCOME trial and Canagliflozin Cardiovascular Assessment Study: Looking beyond the obvious
by: Rishad Ahmed, et al.
Published: (2017-01-01) -
Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
by: Santos Cavaiola T, et al.
Published: (2018-04-01) -
Sodium-glucose cotransporter 2 inhibitors with insulin in type 2 diabetes: Clinical perspectives
by: Mathew John, et al.
Published: (2016-01-01) -
Euglycemic diabetic ketoacidosis caused by canagliflozin: a case report
by: Masafumi Fukuda, et al.
Published: (2020-01-01)